Form 497 LAZARD FUNDS INC
THE LAZARD FUNDS, INC.
Supplement to Current Summary Prospectus and Prospectus
Effective as of April 1, 2021 (the "Effective Date"), the following replaces the table in "Fees and Expenses" in the Summary Prospectus and "Summary Section—Lazard Emerging Markets Equity Advantage Portfolio—Fees and Expenses" in the Prospectus:
Institutional Shares | Open Shares | R6 Shares | |||||
Annual Portfolio Operating Expenses (expenses that you pay each year as a percentage of the value of your investment) | |||||||
Management Fees* | .75% | .75% | .75% | ||||
Distribution and Service (12b-1) Fees | None | .25% | None | ||||
Other Expenses | 2.34% | 3.22% | 2.34% | ** | |||
Total Annual Portfolio Operating Expenses | 3.09% | 4.22% | 3.09% | ||||
Fee Waiver and/or Expense Reimbursement*** | 2.19% | 3.07% | 2.24% | ||||
Total Annual Portfolio Operating Expenses After Fee Waiver and/or Expense Reimbursement | .90% | 1.15% | .85% |
* | Restated to reflect current management fee. |
** | Based on estimated amounts for the current fiscal year, using amounts for Institutional Shares from the last fiscal year. |
*** | Reflects a contractual agreement by Lazard Asset Management LLC (the “Investment Manager”) to waive its fee and, if necessary, reimburse the Portfolio until April 30, 2022, to the extent Total Annual Portfolio Operating Expenses exceed .90%, 1.15% and .85% of the average daily net assets of the Portfolio’s Institutional Shares, Open Shares and R6 Shares, respectively, exclusive of taxes, brokerage, interest on borrowings, fees and expenses of “Acquired Funds,” fees and expenses related to filing foreign tax reclaims and extraordinary expenses. This expense limitation agreement can only be amended by agreement of the Fund, upon approval by the Fund’s Board of Directors, and the Investment Manager to lower the net amount shown and will terminate automatically in the event of termination of the Management Agreement between the Investment Manager and the Fund, on behalf of the Portfolio. |
Effective as of the Effective Date, the following replaces the table in "Example" in the Summary Prospectus and "Summary Section— Lazard Emerging Markets Equity Advantage Portfolio—Example" in the Prospectus:
1 year | 3 years | 5 years | 10 years | ||||
Institutional Shares | $ 92 | $ 748 | $ 1,429 | $ 3,248 | |||
Open Shares | $ 117 | $ 1,001 | $ 1,898 | $ 4,203 | |||
R6 Shares | $ 87 | $ 743 | $ 1,424 | $ 3,244 |
Effective as of the Effective Date, the following replaces any contrary information in the first table in "Fund Management—Investment Manager" in the Prospectus:
Name of Portfolio | Investment Management Fee Payable |
Effective Annual Rate of Investment Management Fee Paid | ||
Emerging Markets Equity Advantage Portfolio | .75% | .00% |
Effective as of the Effective Date, the following replaces any contrary information in the second table in "Fund Management—Investment Manager" in the Prospectus:
Name of Portfolio | Institutional Shares |
Open Shares |
R6 Shares | |||
Emerging Markets Equity Advantage Portfolio†††† | .90% | 1.15% | .85% |
†††† This agreement will continue in effect until April 30, 2022.
Dated: March 29, 2021
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Century Therapeutics (IPSC) to Acquire Clade Therapeutics, Announces $60M Private Placement
- Lazard (LAZ) Reports March 2024 Assets Under Management
- Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN)
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!